Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 25;3(3):e001002.
doi: 10.1161/JAHA.114.001002.

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population

Konstantinos C Siontis  1 , Jeffrey B Geske  2 , Kevin Ong  2 , Rick A Nishimura  2 , Steve R Ommen  2 , Bernard J Gersh  2
Affiliations

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population

Konstantinos C Siontis et al. J Am Heart Assoc. .

Abstract

Background: Atrial fibrillation (AF) is a common sequela of hypertrophic cardiomyopathy (HCM), but evidence on its prevalence, risk factors, and effect on mortality is sparse. We sought to evaluate the prevalence of AF, identify clinical and echocardiographic correlates, and assess its effect on mortality in a large high-risk HCM population.

Methods and results: We identified HCM patients who underwent evaluation at our institution from 1975 to 2012. AF was defined by known history (either chronic or paroxysmal), electrocardiogram, or Holter monitoring at index visit. We examined clinical and echocardiographic variables in association with AF. The effect of AF on overall and cause-specific mortality was evaluated with multivariate Cox proportional hazards models. Of 3673 patients with HCM, 650 (18%) had AF. Patients with AF were older and more symptomatic (P<0.001). AF was less common among patients with obstructive HCM phenotype and was associated with larger left atria, higher E/e' ratios, and worse cardiopulmonary exercise tolerance (all P values<0.001). During median (interquartile range) follow-up of 4.1 (0.2 to 10) years, 1069 (29%) patients died. Patients with AF had worse survival compared to those without AF (P<0.001). In multivariate analysis adjusted for established risk factors of mortality in HCM, the hazard ratio (95% confidence interval) for the effect of AF on overall mortality was 1.48 (1.27 to 1.71). AF did not have an effect on sudden or nonsudden cardiac death.

Conclusions: In this large referral HCM population, approximately 1 in 5 patients had AF. AF was a strong predictor of mortality, even after adjustment for established risk factors.

Keywords: atrial fibrillation; hypertrophic cardiomyopathy; mortality.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan‐Meier's survival analysis for HCM patients with and without AF and expected survival of an age‐ and sex‐matched general U.S. population. Survival was worse in HCM patients with AF than those without AF (P<0.001), and, even in the absence of AF, it was worse than the expected survival of an age‐ and sex‐matched population (P<0.001). AF indicates atrial fibrillation; HCM, hypertrophic cardiomyopathy.
See this image and copyright information in PMC

References

    1. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001; 104:2517-2524. - PubMed
    1. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy‐related death: revisited in a large non‐referral‐based patient population. Circulation. 2000; 102:858-864. - PubMed
    1. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, Bongioanni S, Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39:301-307. - PubMed
    1. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, Matsumura Y, Yabe T, Takata J, Doi YL. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy‐results from Kochi RYOMA Study. Circ J. 2009; 73:1599-1605. - PubMed
    1. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999; 281:650-655. - PubMed

LinkOut - more resources